Lipocine (STU:2VT0) E10: €-3.94 (As of Mar. 2026)


STU:2VT0 Lipocine Inc STU:2VT0
50 GF Score
Price €3.94
GF Value €2.90
! 4 Warning Signs
View Full Analysis

What is Lipocine E10?

Lipocine STU:2VT0 50 E10 is €-3.94 as of Mar. 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 50/100 and a GF Value™ of €2.90. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Lipocine's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.467. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-3.94 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Lipocine was 67.20% per year. The lowest was 17.10% per year. And the median was 42.15% per year.

As of today (2026-07-01), Lipocine's current stock price is €3.944. Lipocine's E10 for the quarter that ended in Mar. 2026 was €-3.94. Lipocine's Shiller PE Ratio of today is .


Lipocine  (STU:2VT0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Lipocine E10 Related Terms


Lipocine E10 Historical Data

* Premium members only.

The historical data trend for Lipocine's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine E10 Chart

Lipocine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -268.69 -13.94 -19.72 -8.68 -4.25

Lipocine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.87 -12.38 -12.77 -4.25 -3.94

STU:2VT0 vs NCEL, PTN, ALLR: E10 Comparison

For the Biotechnology subindustry, Lipocine's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lipocine's Shiller PE Ratio falls into.


STU:2VT0
50GF Score
Lipocine Inc STU:2VT0
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lipocine E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lipocine's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.467/330.2130*330.2130
=-0.467

Current CPI (Mar. 2026) = 330.2130.

Lipocine Quarterly Data

per share eps CPI Adj_EPS
201606 -4.842 241.018 -6.634
201609 -2.726 241.428 -3.728
201612 -2.579 241.432 -3.527
201703 -4.133 243.801 -5.598
201706 -4.690 244.955 -6.322
201709 -3.138 246.819 -4.198
201712 -3.591 246.524 -4.810
201803 -1.792 249.554 -2.371
201806 -2.183 251.989 -2.861
201809 -1.748 252.439 -2.287
201812 -2.241 251.233 -2.946
201903 -2.106 254.202 -2.736
201906 -2.106 256.143 -2.715
201909 -1.852 256.759 -2.382
201912 -1.530 256.974 -1.966
202003 -2.154 258.115 -2.756
202006 -1.962 257.797 -2.513
202009 -1.010 260.280 -1.281
202012 -0.838 260.474 -1.062
202103 -0.571 264.877 -0.712
202106 -1.129 271.696 -1.372
202109 -0.578 274.310 -0.696
202112 2.106 278.802 2.494
202203 -0.617 287.504 -0.709
202206 -0.577 296.311 -0.643
202209 -0.525 296.808 -0.584
202212 -0.406 296.797 -0.452
202303 -0.710 301.836 -0.777
202306 -0.628 305.109 -0.680
202309 -1.190 307.789 -1.277
202312 -0.385 306.746 -0.414
202403 0.607 312.332 0.642
202406 -0.530 314.175 -0.557
202409 -0.396 315.301 -0.415
202412 0.315 315.605 0.330
202503 -0.324 319.799 -0.335
202506 -0.355 322.561 -0.363
202509 -0.503 324.800 -0.511
202512 -0.359 324.054 -0.366
202603 -0.467 330.213 -0.467

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-3.94 mean?
Lipocine (STU:2VT0) has a E10 of €-3.94 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Lipocine and its competitors.
Is Lipocine's E10 too high?
Lipocine's current E10 is €-3.94. Overall, Lipocine has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's E10 compare to NCEL and PTN?
Lipocine's E10 of €-3.94 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Lipocine and its competitors. Lipocine's current E10 is €-3.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current E10 of €-3.94. The stock's GF Value™ is €2.90, compared to a current price of €3.94 — trading 36% above its estimated fair value. The current E10 is €-3.94. Lipocine's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current E10 is €-3.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (STU:2VT0) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of €3.94 is trading 36% above its estimated GF Value™ of €2.90.

Key valuation signals for STU:2VT0:

  • E10: €-3.94
  • GF Value™: €2.90 vs. price of €3.94 (36% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lipocine Business Description

Other Exchanges LPCN:USA
Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
50GF Score

Get the complete analysis for STU:2VT0

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€2.90
GF Value